Navigation Links
Study Shows Promise For Simplified Treatment of HIV Infection

A preliminary study indicates that using a single boosted protease inhibitor instead of the standard regimen of 3 drugs for maintenance therapy may be an effective treatment// for select patients with HIV infection, according to a study in the August 16 issue of JAMA, a theme issue on HIV/AIDS.

Susan Swindells, M.B.B.S., of the University of Nebraska Medical Center, Omaha, presented the findings of the study today at a JAMA media briefing at the International AIDS Conference in Toronto.

The long-term adverse effects, expense, and difficulty of sustained adherence to multidrug antiretroviral regimens have prompted studies of simpler therapies for human immunodeficiency virus type 1 (HIV-1) infection. Treatment cessation, intermittent therapy, and induction-maintenance (a few months of triple therapy followed by simplified therapy) regimens have been evaluated with mostly inferior results, according to background information in the article.

Dr. Swindells and colleagues conducted a study to determine whether a simplified maintenance therapy with the antiretroviral medication “boosted” atazanavir alone after virologic suppression (cessation of detectable HIV virus replication) would not markedly increase the risk of virologic failure. Protease inhibitors, such as atazanavir, are often combined with a small dose of ritonavir to increase blood levels – a phenomenon known as “boosting.” This regimen was selected because of low pill burden, once-daily dosing, safety, and unique resistance profile. The 24-week pilot study, conducted between Sept. 2004 and April 2006, included 36 HIV-infected adults with virologic suppression for 48 weeks or longer receiving their first protease inhibitor (PI)–based regimen. Participants switched PIs to atazanavir-ritonavir at entry and discontinued nucleoside analog reverse transcriptase inhibitors (NRTIs) after 6 weeks. Virologic failure was defined as two consecutive HIV-1 RNA measurements of 200 copies/ mL or more. The final analysis included 34 patients.

Virologic success (absence of failure) through 24 weeks of simplified therapy occurred in 91 percent of patients (31 of 34). Three participants experienced virologic failure at 12, 14, and 20 weeks after simplification. Resistance testing at failure did not identify protease inhibitor resistance mutations. Atazanavir concentrations in the blood at failure were low or below detection in 2 of 3 participants experiencing failure, indicating these patients may not have taken the prescribed doses. There were no treatment discontinuations for adverse events after simplification and no significant changes in CD4 cell counts.

“In this pilot study, the data suggest that simplified maintenance therapy with atazanavir-ritonavir alone in patients who have never experienced treatment failure may be efficacious in maintaining HIV-1 RNA suppression below 200 copies/mL for 24 weeks after discontinuing NRTIs,” the authors write. “Maintenance therapy with a single boosted PI offers a treatment strategy with potentially less complexity, pill burden, long-term complications, and cost.”

(Source: Nwswise)
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... ... February 22, 2017 , ... The ... Insights to help small practices in Delaware, New Jersey, Pennsylvania and West Virginia ... Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). , This technical ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of American ... that family members or friends have also commented about their poor hearing. However, ... hearing aids. One reason, suggested by 89 percent of American respondents, is that ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is a nonprofit ... , Established in 1977, our organization was at the forefront in working with ... civilian life were evident and served as the catalyst for the establishing the ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... for supply chain management (SCM) and spend management, today announced that Keppel Corporation ... time, and simplify expense tracking. , “We are excited to announce the ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... senior director at PolicyLink, will be the keynote speaker at its second Professional ... Men of Color Framework, which develops comprehensive strategies to create and expand opportunities ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... global market was valued at $3,453 million in 2015 and is projected to reach ... The arthroscopic implants segment held nearly two-fifths of the total market in 2015. ... ... Research Logo ...
(Date:2/22/2017)... Feb. 22, 2017   Protein Sciences Corporation , ... Flublok® Influenza Vaccine , announced today that they donated ... Vaccine Introduction (PIVI) and the Mongolian Ministry of Health ... the flu.  The doses of Flublok have been distributed ... for health care workers, pregnant women, and ...
(Date:2/22/2017)... MIAMI , Feb. 22, 2017  Tri-Source Pharma ... restructuring efforts. A series of newly appointed positions were ... founder and CEO, Robert DiCrisci , in the ... plan and management of the recently consolidated subsidiary companies. ... Tri-Source,s executive team will be composed of the following ...
Breaking Medicine Technology: